Intravenous Iron Drugs Market Report 2026

Intravenous Iron Drugs Market Overview

• Intravenous Iron Drugs market size has reached to $3.81 billion in 2025 • Expected to grow to $6.34 billion in 2030 at a compound annual growth rate (CAGR) of 10.7% • Growth Driver: Growing Incidence Of Chronic Kidney Disease (CKD) Fueling The Market Due To Rising Prevalence Of Risk Factors And Associated Mortality Rates • Market Trend: Focus On Intravenous Iron Replacement Therapy For Improved Patient Outcomes • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Intravenous Iron Drugs Market?

Intravenous iron drugs are iron formulations administered directly into the bloodstream to treat iron deficiency and iron deficiency anemia, especially in patients who cannot tolerate or do not respond adequately to oral iron supplements. These drugs work by rapidly increasing iron levels, facilitating hemoglobin production, and improving oxygen transport, alleviating symptoms such as fatigue and weakness. The main product types for intravenous iron drugs include iron dextran, iron sucrose, ferric carboxymaltose, and other product types. Iron dextran is an injectable iron supplement used for rapid iron replenishment in patients with severe deficiencies when oral iron is ineffective or intolerable. These drugs are used for various indications such as chronic kidney disease, inflammatory bowel disease, cancer, and other diseases. They are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

What Is The Intravenous Iron Drugs Market Growth Forecast?

The intravenous iron drugs market size is expected to see rapid growth in the next few years. It will grow to $6.34 billion in 2030 at a compound annual growth rate (CAGR) of 10.7%. The growth in the forecast period can be attributed to rising chronic disease burden, growth in dialysis patient population, increasing cancer-related anemia cases, preference for rapid hemoglobin correction, expansion of outpatient infusion services. Major trends in the forecast period include increasing use in iron deficiency anemia management, rising adoption in chronic kidney disease patients, growing preference over oral iron therapies, expansion of single-dose iron formulations, higher utilization in oncology and gastroenterology.

Global Intravenous Iron Drugs Market Segmentation

1) By Product Type: Iron Dextran, Iron Sucrose, Ferric Carboxymaltose, Other Product Types 2) By Indication: Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer, Other Diseases 3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy Subsegments: 1) By Iron Dextran: Low Molecular Weight Iron Dextran, High Molecular Weight Iron Dextran 2) By Iron Sucrose: Standard Iron Sucrose Injection, Iron Sucrose Complex 3) By Ferric Carboxymaltose: Single-Dose Ferric Carboxymaltose, Multiple-Dose Ferric Carboxymaltose 4) By Other Product Types: Ferumoxytol, Ferric Derisomaltose, Sodium Ferric Gluconate

What Is The Driver Of The Intravenous Iron Drugs Market?

The growing incidence of chronic kidney disease (CKD) is expected to propel the growth of the intravenous iron drugs market going forward. Chronic kidney disease (CKD) refers to the gradual loss of kidney function over time, leading to the kidneys' inability to effectively filter waste and excess fluids from the blood. The growing incidence of chronic kidney disease (CKD) is due to increasing rates of diabetes and hypertension, which contribute to kidney damage over time. Intravenous iron drugs help chronic kidney disease patients by replenishing iron stores, correcting anemia, and improving hemoglobin levels, which enhances oxygen transport and reduces the need for erythropoiesis-stimulating agents. For instance, in July 2025, according to Hamadan University of Medical Sciences, a Iran-based university, the global number of newly diagnosed chronic kidney diseases is projected to rise to 25.06 million by 2030. Therefore, the growing incidence of chronic kidney disease (CKD) is driving the growth of the intravenous iron drugs industry.

Key Players In The Global Intravenous Iron Drugs Market

Major companies operating in the intravenous iron drugs market are Pharmacosmos A/S, American Regent Inc., Fresenius SE & Co. KGaA, Sandoz Group AG, Hikma Pharmaceuticals plc, Rockwell Medical Inc., Daiichi Sankyo Company Ltd., CSL Limited, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Zydus Lifesciences Limited, Vifor Pharma Management Ltd., Galenica Ltd., Aspen Pharmacare Holdings Limited, Lupin Limited, Aurobindo Pharma Limited, Jiangsu Hengrui Pharmaceutical Co. Ltd., Kissei Pharmaceutical Co. Ltd., Nanjing Hicin Pharmaceutical Co. Ltd

Global Intravenous Iron Drugs Market Trends and Insights

Major companies operating in the intravenous iron drugs market are focusing on developing innovative therapies, such as intravenous (IV) iron replacement therapy, to improve efficacy, safety, and patient outcomes. Intravenous (IV) iron replacement therapy is a medical treatment that delivers iron directly into the bloodstream through an intravenous infusion. This therapy treats iron deficiency and anemia, especially in patients who cannot tolerate or adequately absorb oral iron supplements. For instance, in June 2023, Daiichi Sankyo Company Limited, a Japan-based pharmaceutical company that specializes in innovative drug development and healthcare solutions, announced that the U.S. Food and Drug Administration (FDA) had approved Injectafer (ferric carboxymaltose injection) for treating iron deficiency in adult patients with heart failure classified as New York Heart Association class II/III to enhance exercise capacity. Injectafer is a widely used intravenous iron therapy known for rapidly replenishing iron levels in patients who cannot tolerate or do not respond well to oral iron supplements.

What Are Latest Mergers And Acquisitions In The Intravenous Iron Drugs Market?

In June 2024, Menarini Asia-Pacific, a Singapore-based pharmaceutical and healthcare company, expanded its partnership with Pharmacosmos A/S for an undisclosed amount. Through this partnership expansion, Menarini secured exclusive rights to commercialize MonoFer® in Singapore and Malaysia, strengthening its hematology portfolio and enhancing regional access to advanced IV iron therapies for iron deficiency management. Pharmacosmos A/S is a Denmark-based pharmaceutical company that offers intravenous (IV) iron drugs.

Regional Insights

North America was the largest region in the intravenous iron drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Intravenous Iron Drugs Market?

The intravenous iron drugs market consists of sales of ferric gluconate, ferumoxytol, ferric derisomaltose, and sodium ferric gluconate. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Intravenous Iron Drugs Market Report 2026?

The intravenous iron drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the intravenous iron drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.